scholarly journals Bladder Wall Thickness is Associated with Responsiveness of Storage Symptoms to Alpha-Blockers in Men with Lower Urinary Tract Symptoms

2012 ◽  
Vol 53 (7) ◽  
pp. 487 ◽  
Author(s):  
Jung Soo Park ◽  
Ho Won Lee ◽  
Seung Wook Lee ◽  
Hong Sang Moon ◽  
Hae Young Park ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Wall Thickness ◽  
Lower Urinary Tract ◽  
Bladder Wall ◽  
Bladder Wall Thickness ◽  
Alpha Blockers ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals The relationship between bladder wall thickness and lower urinary tract symptoms: Does bladder wall thickness change after alpha-blocker therapy with alfuzosin?

2014 ◽  
Vol 8 (1-2) ◽  
pp. 26 ◽  
Author(s):  
Ayhan Karakose ◽  
Ozgu Aydogdu ◽  
Yusuf Ziya Atesci
Keyword(s):  
Urinary Tract ◽  
Wall Thickness ◽  
Lower Urinary Tract ◽  
Bladder Wall ◽  
Blocker Therapy ◽  
Bladder Wall Thickness ◽  
Urinary Tract Symptoms ◽  
Significant Difference ◽  
Group 2 ◽  
Lower Urinary

Introduction: We evaluate the association between lower urinary tract symptoms (LUTS) and bladder wall thickness (BWT) and investigate whether alfuzosin might improve BWT.Methods: We retrospectively reviewed the data of 164 patients with LUTS. Patients were divided into 2 groups according to BWT(Group 1: BWT ≤5 mm, n = 69; Group 2: BWT >5 mm, n = 95). Age, international prostate symptom score (IPSS), maximum and average urinary flow rates (Qmax and Qave), quality of life (QoL), postvoid residual (PVR) urine volume, prostate volume and prostate-specific antigen (PSA) were compared between the 2 groups. In total, 102 patients underwent transurethral resection of the prostate (TURP) and 62 patients were treated with alfuzosin. We compared BWT, Qmax, Qave, IPSS, QoL, PVR and PSA before and at the sixth month of alfuzosin therapy. A p value of <0.05 was considered statistically significant.Results: The mean BWT of Group 1 was 3.72 ± 0.56 mm and Group 2 was 6.43 ± 1.13 mm. There was a significant difference between the 2 groups in terms of mean Qmax and PVR. There was no statistical difference between the groups in terms of Qave, IPSS, QoL, prostate volume and PSA. There was significant difference between BWT before (6.8 ± 2.1) and after (4.6 ± 1.3) treatment with alfuzosin in 62 patients (p = 0.02). There was a significant difference between pre- and post-treatment values of mean Qmax, Qave, IPSS, QoL score, and PVR with alfuzosin.Conclusion: BWT is a non-invasive and effective test to evaluate patients with lower urinary tract obstruction and may be used for showing the effectiveness of alpha-blocker therapy in patients with LUTS.

scholarly journals Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis

2021 ◽  
Vol 13 ◽  
pp. 175628722199328
Author(s):  
Andrea Mari ◽  
Alessandro Antonelli ◽  
Luca Cindolo ◽  
Ferdinando Fusco ◽  
Andrea Minervini ◽  
...  
Keyword(s):  
Systematic Review ◽  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostatic Hyperplasia ◽  
Safety And Efficacy ◽  
Alpha Blockers ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Background: Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are a bothersome frequent symptom in adult males. This systematic review analyzed the available evidence on the pharmacokinetic and pharmacodynamic features of alfuzosin, and its clinical efficacy both as monotherapy and in combination with other drugs for the treatment of male LUTS/BPH. Methods: A systematic review of the last 10 years was performed using the MEDLINE, EMBASE and Cochrane libraries in March 2020. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42020136120) and is available in full on the University of York website. Results: Alfuzosin is a quinazoline derivative and, although a nonspecific α1-blocker, exhibits a selective concentration in the prostate compared with plasma in patients with BPH. Three registration trials assessed the safety and efficacy of alfuzosin. The 10 mg daily formulation has a three-layered matrix containing the active substance between two inactive coats allowing a drug release over 20 h. Alfuzosin showed high tolerability, few vasodilatory effects and a low rate of ejaculation disorders over older alpha-blocking compounds thanks to the high uroselectivity of alfuzosin and its preferential concentration at urinary level. Six randomized clinical trials (RCTs) assessed efficacy and safety of alfuzosin versus other alpha-blockers ± placebo: three studies comparing with tamsulosin, one with doxazosin, and two with silodosin or tamsulosin. One RCT investigated the clinical outcomes of alfuzosin with finasteride, two with propiverine and two with phosphodiesterase-5 inhibitors. Conclusions: Alfuzosin is an effective drug for the treatment of LUTS/BPH, with a lower rate of sexual disorders compared with other alpha-blockers. Alfuzosin is also safe with low adverse events in case of concomitant antihypertensive therapy and in patients with cardiovascular morbidity. Safety and efficacy of alfuzosin has been reported also in case of combination therapy with antimuscarinic agents and PDE5i.

Sign in / Sign up

Export Citation Format

Share Document